Response to Lusutrombopag in portal hypertension with Splenomegaly:retrospective study

Response to Lusutrombopag in portal hypertension with Splenomegaly:retrospective study - Response to Lusutrombopag in Splenomegaly

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031354

Enrollment

Registered

2018-02-18

Start date

2018-02-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thrombocytopenia with splenomegaly

Interventions

Multicenter, single-arm, open-label trial

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: thrombocytic patients with splenomegaly

Exclusion criteria

Exclusion criteria: 1.Patients with a hematologic malignancy. 2.Active malignancy at time of study entry except HCC. 3.Patients who underwent liver transplantation 4.Patients with a severe liver dysfunction (Child-pugh C) 5.Patients with a medical history of thrombosis. 6.Patients with a medical history of thrombotic disease adult patients. 7.Women who are pregnant or breastfeeding 8.Severe GI bleeding. 9.Not appropriate for this study

Design outcomes

Primary

Measure	Time frame
The endpoint measurement was the comparison of change platelet counts in a mild splenomegaly and a severe splenomegaly group.	—

Secondary

Measure	Time frame
The secondary endpoints were an investigation of the response to the trial drug associated with clinical characteristics including a spleen size.	—

Countries

Japan

Contacts

Public ContactUojima Haruki

Kitasato University School of Medicine Department of Gastroenterology

kiruha@kitasto-u.ac.jp042-778-8390

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026